Myriad Genetics, Inc.
(NASDAQ : MYGN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. 1.32%697.332.6%$644.85m
MRNAModerna, Inc. -0.55%123.640.0%$634.51m
AMGNAmgen, Inc. -0.34%226.971.4%$624.69m
GILDGilead Sciences, Inc. -1.43%62.861.0%$494.49m
VRTXVertex Pharmaceuticals, Inc. -1.01%283.451.9%$355.83m
ILMNIllumina, Inc. -1.61%190.383.2%$291.37m
SNSSSunesis Pharmaceuticals, Inc. -5.81%4.050.7%$283.11m
BIIBBiogen, Inc. -1.42%197.781.8%$184.42m
SAVACassava Sciences, Inc. -18.00%41.870.0%$173.71m
BNTXBioNTech SE -1.27%128.350.0%$100.39m
NRBONeuroBo Pharmaceuticals, Inc. -6.44%15.540.0%$89.03m
NVAXNovavax, Inc. -6.42%21.0075.6%$85.66m
BMRNBioMarin Pharmaceutical, Inc. -0.09%84.844.2%$76.07m
EXASEXACT Sciences Corp. -2.74%33.4117.6%$71.49m
CRSPCRISPR Therapeutics AG -2.68%63.160.6%$69.53m

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.